Рак легкого и беременность

По данным мировой статистики, рак легкого (РЛ) занимает 2-е ранговое место в структуре онкологической заболеваемости среди женщин. Ведение РЛ, ассоциированного с беременностью, представляет собой клиническую дилемму, поскольку необходимо учитывать возможные риски в отношении не только матери, но и плода. Целью работы явилось изучение существующих литературных данных о диагностике, тактике ведения и лечебных подходах при РЛ, ассоциированном с беременностью. По данным литературных источников и представленных клинических наблюдений показаны неутешительные результаты: практически не наблюдалось ответа на химиотерапию (ХТ) у пациенток, получавших ХТ комбинациями платины с винорелбином, паклитакселом и этопозидом во время беременности и после родов, при этом сделан предварительный вывод о том, что изменение фармакокинетики химиопрепаратов может поставить под угрозу лечение онкологического заболевания во время беременности. Применение хирургического и лучевого методов лечения зависит от конкретной клинической ситуации, стадии и гистотипа опухоли, а также срока беременности. Заключение. Таким образом, как диагностические, так и лечебные мероприятия в отношении беременных женщин с РЛ должны быть персонализированными и выполняться специальной мультидисциплинарной командой, включающей в себя химиотерапевта, радиотерапевта, онколога-хирурга и акушера-гинеколога.

1. Voulgaris E., Pentheroudakis G., Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg. Oncol. 2011; 20 (4): e175-185. https://doi.org/10.1016/j.suronc.2011.06.002.

2. Pentheroudakis G., Pavlidis N. Gastrointestinal, urologic and lung malignancies during pregnancy. Recent Results Cancer Res. 2008; 178: 137-164. https://doi.org/10.1007/978-3-540-71274-9_13.

3. Boussios S., Han S.N., Fruscio R. et al. Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer. 2013; 82 (3): 499-505. https://doi.org/10.1016/j.lungcan.2013.09.002.

4. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2006. CA Cancer J. Clin. 2006; 56 (2): 106-130. https://doi.org/10.3322/canjclin.56.2.106.

5. Barr J.S. Placental metastases from a bronchial carcinoma. J. Obstet. Gynaecol. Br. Emp. 1953; 60 (6): 895-897. https://doi.org/10.1111/j.1471-0528.1953.tb07292.x.

6. Azim H.A. Jr., Peccatori F.A., Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer. 2010; 67 (3): 251-256. https://doi.org/10.1016/j.lungcan.2009.10.006.

7. Hayama M., Chida M., Tamura M. et al. Unexpected rapid growth of estrogen receptor positive lung cancer during pregnancy. Ann. Thorac. Cardiovasc. Surg. 2014; 20 (4): 325-328. https://doi.org/10.5761/atcs.cr.12.01934.

8. Sarıman N., Levent E., Yener N.A. et al. Lung cancer and pregnancy. Lung Cancer. 2013; 79 (3): 321-323. https://doi.org/10.1016/j.lungcan.2012.11.014.

9. Ceauşu M., Hostiuc S., Sajin M. et al. Gestational lung adenocarcinoma: case report. Int. J. Surg. Pathol. 2014; 22 (7): 663-666. https://doi.org/10.1177/1066896914531816.

10. Kim J.W., Kim J.S., Cho J.Y., Lee D.H. Successful video-assisted thoracoscopic lobectomy in a pregnant woman with lung cancer. Lung Cancer. 2014; 85 (2): 331-334. https://doi.org/10.1016/j.lungcan.2014.05.022.

11. Neves I., Mota P.C., Hespanhol V.P. Lung cancer during pregnancy: an unusual case. Rev. Port. Pneumol. 2014; 20 (1): 46-49. https://doi.org/10.1016/j.rppneu.2013.06.005.

12. Gil S., Goetgheluck J., Paci A. et al. Efficacy and safety of gefitinib during pregnancy: case report and literature review. Lung Cancer. 2014; 85 (3): 481-484. https://doi.org/10.1016/j.lungcan.2014.06.003.

13. Wang A., Kubo J., Luo J. et al. Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational study prospective cohort. Ann. Oncol. 2015; 26 (1): 221-230. https://doi.org/10.1093/annonc/mdu470.

14. Lortet-Tieulent J., Soerjomataram I., Ferlay J. et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014; 84 (1): 13-22. https://doi.org/10.1016/j.lungcan.2014.01.009.

15. Azim H.A. Jr., Peccatori F.A., Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat. Rev. 2010; 36 (2): 101-109. https://doi.org/10.1016/j.ctrv.2009.11.007.

16. Pavlidis N., Peccatori F.A., Lofts F., Greco A.F. Cancer of unknown primary during pregnancy: an exceptionally rare coexistence. Anticancer Res. 2015; 35 (1): 575-579. Available at: https://ar.iiarjournals.org/content/35/1/575

17. Pentheroudakis G., Orecchia R., Hoekstra H.J. et al. Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (Suppl. 5): v266-273. https://doi.org/10.1093/annonc/mdq198.

18. Olsen J., Pedersen L.H. Reproductive health indicators and fetal medicine - many things will change. Scand. J. Work Environ. Health. 2016; 42 (6): 561-562. https://doi.org/10.5271/sjweh.3596.

19. Soberanis Pina P., Lara-Mej´ıa L., Matias-Cruz V. et al. Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer. Front. Oncol. 2023; 13:1108124. https://doi.org/10.3389/fonc.2023.1108124.

20. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71 (3): 209-249. https://doi.org/10.3322/caac.21660.

21. Arrieta O., Zatarain-Barrón Z.L., Aldaco F. et al. Lung cancer in Mexico. J. Thorac. Oncol. 2019; 14 (10):1695-700. https://doi.org/10.1016/j.jtho.2019.05.018.

22. Bellido C., Barbero P., Forcén L. et al. Lung adenocarcinoma during pregnancy: clinical case and literature review. J. Maternal. Fetal Neonatal Med. 2019; 32 (19): 3300-3302. https://doi.org/10.1080/14767058.2018.1461830.

23. Passaro A., Leighl N., Blackhall F et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol. 2022. 33 (5): 466-487. https://doi.org/10.1016/j.annonc.2022.02.003.

24. Rosell R., Cardona A.F., Arrieta O. et al. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br. J. Cancer. 2021; 125: 1602-1611. https://doi.org/10.1038/s41416-021-01519-2.

25. Corrales-Rodrıguez L., Arrieta O., Mas L. et al. An international epidemiological analysis of young patients with nonsmall cell lung cancer (AduJov-CLICaP). Lung Cancer. 2017; 113: 30-36. https://doi.org/10.1016/j.lungcan.2017.08.022.

26. Dagogo-Jack I., Gainor J.F., Porter R.L. et al. Clinicopathologic features of NSCLC diagnosed during pregnancy or the peripartum period in the era of molecular genotyping. J. Thorac. Oncol. 2016; 11 (9): 1522-1528. https://doi.org/10.1016/j.jtho.2016.05.031.

27. Jin J., Wu X., Yin J. et al. Identification of genetic mutations in cancer: Challenge and opportunity in the new era of targeted therapy. Front. Oncol. 2019; 9: 263. https://doi.org/10.3389/FONC.2019.00263.

28. Kooijman J.J., van Riel W.E., Dylus J. et al. Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Front. Oncol. 2022; 12: 953013. https://doi.org/10.3389/FONC.2022.953013.

29. Qi Y., Xia X., Shao L. et al. An updated network metaanalysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. Front. Oncol. 2022; 12: 616546. https://doi.org/10.3389/FONC.2022.616546.

30. Rayego-Mateos S., Rodrigues-Diez R., Morgado-Pascual J.L. et al. Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage. Mediators Inflamm. 2018; 2018: 8739473. https://doi.org/10.1155/2018/8739473.

31. Robinson A.A., Watson W.J., Leslie K.K. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol. 2007; 8 (8): 738-743. https://doi.org/10.1016/S1470-2045(07)70242-5.

32. Boudy A.S., Grausz N., Selleret L. et al. Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma. Lung Cancer. 2021; 161: 68-75. https://doi.org/10.1016/j.lungcan.2021.09.001.

33. Kim Y., Lee S.H., Ahn J.S. et al. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res. Treat. 2019; 51 (2): 502-509. https://doi.org/10.4143/CRT.2018.117.

34. Orefice R. Immunology and the immunological response in pregnancy. Best Pract. Res. Clin. Obstetю Gynaecol. 2021. 76: 3-12. https://doi.org/10.1016/J.BPOBGYN.2020.07.013.

35. Kareva I. Immune suppression in pregnancy and cancer: parallels and insights. Transl. Oncol. 2020; 13 (7): 100759. https://doi.org/10.1016/J.TRANON.2020.100759.

36. Rodriguez-Lara V., Hernandez-Martinez J.M., Arrieta O. Influence of estrogen in non-small cell lung cancer and its clinical implications. J. Thorac Dis. 2018; 10 (1): 482-497. https://doi.org/10.21037/JTD.2017.12.61.

37. Кузнецов П.А., Оленев А.С., Джохадзе Л.С., Селиверстова О.М. Влияние ионизирующего излучения на плод. Российский вестник акушера-гинеколога. 2018; 18 (5): 32-35. https://doi.org/10.17116/rosakush20181805132.

38. Rosell R., Cardona A.F., Arrieta O. et al. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br. J. Cancer. 2021; 125 (12): 1602-1611. https://doi.org/10.1038/s41416-021-01519-2.